Home

Subscription

October 2024 issue

September 2024 issue

August 2024 issue

July 2024 issue

June 2024 issue

May 2024 issue

April 2024 issue

April 1, 2024 issue

March 2024 issue

February 2024 issue

January 2024 issue



BACK ISSUES

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006


2012 Issues

December 2012 Issue
• A Christmas Letter
• New Drug Review: Mirabegron (Myrbetriq)
• Index for 2012


November 2012 Issue
• Feature - Pharmacy-Assisted Suicide - at CVS, Rite Aid, Walgreens, Walmart, etc.
• New Drug Review: Tofacitinib citrate (Xeljanz)


October 2012 Issue
• Feature - The Meningitis Tragedy - More Regulation is Not the Answer
• New Drug Review: Elvitegravir/Cobicistat (Stribild)


September 2012 Issue
• Feature - Our Professional Autonomy and the Health of our Patients are at Risk! We Need More Independence in our Practice Responsibilities and More Independent Pharmacies
• New Drug Review: Peginesatide acetate (Omontys)


August 2012 Issue
• Feature - Accreditation of Community Pharmacies Can Have Important Benefits - But the Program Must Have Credibility and Value for the Participants
• New Drug Review: Spinosad (Natroba)


July 2012 Issue
• Feature - The Restrictive and Risky Mail-order Distribution Program for Qsymia Must be Rescinded
• New Drug Review: Ezogabine (Potiga)


June 2012 Issue
• Feature - Is Patient Safety at Risk at CVS? There is a Whistleblower!
• New Drug Review: Aflibercept (Eylea)


May 2012 Issue
• Feature - The "Tyranny of the Urgent" Must Not Compromise our Commitment to our Priorities
• New Drug Review: Ingenol mebutate (Picato)


April 2012 Issue
• Feature - We Must Prevent "Reform" from Taking the "Care" out of Health Care!
• New Drug Review: Indacaterol maleate (Arcapta)


March 2012 Issue
• Feature - Many Prescription Medications Should be Available Without a Prescription from a Pharmacist
• New Drug Review: Fidaxomicin (Dificid)


February 2012 Issue
• Feature - CVS - Criminal Charges are Needed!
• New Drug Review: Roflumilast (Daliresp)


January 2012 Issue
• Feature - Pharmacy Must Establish its Own Prescription Benefit Program
• New Drug Review: Belimumab (Benlysta)